Floatz logo

Sctil

Cervical Cancer

Peking Union Medical College HospitalCell therapyPhase 2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
65/ 100

Competitive context

159 Active assets in the Cervical Cancer cohort.

Asset / SponsorPhaseRating
Vinorelbine
UNICANCER
Phase 2BBB
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
Indocyanine Green
Istanbul University
Phase 4BB
TECHNETIUM-99
Institut de Cancérologie de Lorraine
Phase 3B
CIS-DIAMMINEDICHLOROPLATINUM II
Uganda Cancer Institute
Phase 3B

View all 50 →

Same molecule, other indications

Sctil is also rated in:

gestational trophoblastic neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →
ovarian cancerDormant
CC
Indicative ·
46 / 100
View asset →
digestive system cancerDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →